|
TFAP2A |
transcription factor AP-2 alpha |
- Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
- Negative regulation of activity of TFAP2 (AP-2) family transcription factors
- Negative regulation of activity of TFAP2 (AP-2) family transcription factors
- TFAP2 (AP-2) family regulates transcription of other transcription factors
- Activation of the TFAP2 (AP-2) family of transcription factors
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- TFAP2 (AP-2) family regulates transcription of cell cycle factors
- TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation
|
|
- Branchiooculofacial syndrome (BOFS)
|
|
AR |
androgen receptor |
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
- Ub-specific processing proteases
- RUNX2 regulates osteoblast differentiation
- RUNX2 regulates osteoblast differentiation
|
- Diethylstilbestrol
- Levonorgestrel
- Progesterone
- Spironolactone
- Flutamide
- Oxandrolone
- Fluphenazine
- Testosterone
- Mitotane
- Estrone
- Nilutamide
- Tamoxifen
- Norethisterone
- Drostanolone
- Norgestimate
- Nandrolone phenpropionate
- Ketoconazole
- Acetophenazine
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone propionate
- Oxybenzone
- 1-Testosterone
- Boldenone
- Calusterone
- Periciazine
- Prasterone
- Flufenamic acid
- Stanolone
- (R)-Bicalutamide
- Metribolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone acetate
- LGD2941
- Dimethylcurcumin
- Oxymetholone
- Methyltestosterone
- Norelgestromin
- Stanozolol
- Tetrahydrogestrinone
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- BMS-564929
- S-23
- phenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- Andarine
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- LGD-2226
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Triclosan
- Nandrolone decanoate
- Ulipristal
- Enzalutamide
- Eugenol
- Dienogest
- Norethynodrel
- Norgestrel
- Homosalate
- Enzacamene
- Mibolerone
- Phenothiazine
- Gestrinone
- Apalutamide
- Clascoterone
- Darolutamide
- Esculin
- Ligandrol
- Testosterone cypionate
- Testosterone enanthate
- Testosterone undecanoate
- Stanolone acetate
- Segesterone acetate
- Boldenone undecylenate
- Echinacoside
- Ketodarolutamide
|
- 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
- 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism
- Prostate cancer
- Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease
|
|
KDR |
kinase insert domain receptor |
- Neurophilin interactions with VEGF and VEGFR
- VEGF binds to VEGFR leading to receptor dimerization
- Integrin cell surface interactions
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
|
- Sorafenib
- Sunitinib
- 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
- Cediranib
- Vatalanib
- XL999
- TG-100801
- XL820
- CYC116
- Ramucirumab
- Pegdinetanib
- RAF-265
- ABT-869
- IMC-1C11
- Semaxanib
- Pazopanib
- Midostaurin
- Axitinib
- 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide
- N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide
- N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide
- 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide
- N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE
- N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE
- 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one
- 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one
- N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide
- N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
- N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
- Cabozantinib
- Regorafenib
- Ponatinib
- Lenvatinib
- Nintedanib
- Fostamatinib
- Erdafitinib
- Foretinib
- Ripretinib
- Pralsetinib
|
|
|
MUC1 |
mucin 1, cell surface associated |
- Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC)
- Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)
- Defective GALNT12 causes colorectal cancer 1 (CRCS1)
- Dectin-2 family
- Interleukin-4 and Interleukin-13 signaling
- O-linked glycosylation of mucins
- Termination of O-glycan biosynthesis
|
|
|
|
SMAD7 |
SMAD family member 7 |
- Signaling by BMP
- Downregulation of TGF-beta receptor signaling
- Downregulation of TGF-beta receptor signaling
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- UCH proteinases
- Ub-specific processing proteases
|
|
|
|
SMARCA4 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
- Interleukin-7 signaling
- Formation of the beta-catenin:TCF transactivating complex
- RMTs methylate histone arginines
- Chromatin modifying enzymes
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- EGR2 and SOX10-mediated initiation of Schwann cell myelination
- EGR2 and SOX10-mediated initiation of Schwann cell myelination
|
|
|
|
SP1 |
Sp1 transcription factor |
- PPARA activates gene expression
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Activation of gene expression by SREBF (SREBP)
- Oncogene Induced Senescence
- RNA polymerase II transcribes snRNA genes
- RNA polymerase II transcribes snRNA genes
- Estrogen-dependent gene expression
|
|
|
|
STUB1 |
STIP1 homology and U-box containing protein 1 |
- Downregulation of TGF-beta receptor signaling
- RIPK1-mediated regulated necrosis
- Regulation of necroptotic cell death
- Downregulation of ERBB2 signaling
- Regulation of RUNX2 expression and activity
- Regulation of PTEN stability and activity
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
CDC73 |
cell division cycle 73 |
- Formation of RNA Pol II elongation complex
- Formation of the beta-catenin:TCF transactivating complex
- Hedgehog 'on' state
- RNA Polymerase II Pre-transcription Events
- RNA Polymerase II Transcription Elongation
- E3 ubiquitin ligases ubiquitinate target proteins
|
|
- Primary hyperparathyroidism; Familial hyperparathyroidism (HRPT)
|
|
GNA13 |
G protein subunit alpha 13 |
- NRAGE signals death through JNK
- Rho GTPase cycle
- G alpha (12/13) signalling events
- Thromboxane signalling through TP receptor
- Thrombin signalling through proteinase activated receptors (PARs)
- Thrombin signalling through proteinase activated receptors (PARs)
|
|
|
|
MEN1 |
menin 1 |
- Formation of the beta-catenin:TCF transactivating complex
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Deactivation of the beta-catenin transactivating complex
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- RHO GTPases activate IQGAPs
- Post-translational protein phosphorylation
|
|
- Carcinoid
- Adrenal carcinoma
- Primary hyperparathyroidism; Familial hyperparathyroidism (HRPT)
- Malignant islet cell carcinoma
|
|
PECAM1 |
platelet and endothelial cell adhesion molecule 1 |
- Platelet degranulation
- Cell surface interactions at the vascular wall
- PECAM1 interactions
- Integrin cell surface interactions
- Platelet sensitization by LDL
- Neutrophil degranulation
|
|
|
|
PRKCG |
protein kinase C gamma |
- Calmodulin induced events
- Disinhibition of SNARE formation
- Trafficking of GluR2-containing AMPA receptors
- G alpha (z) signalling events
- WNT5A-dependent internalization of FZD4
- Response to elevated platelet cytosolic Ca2+
|
|
- Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
|
|
RBBP5 |
RB binding protein 5, histone lysine methyltransferase complex subunit |
- Formation of the beta-catenin:TCF transactivating complex
- PKMTs methylate histone lysines
- Deactivation of the beta-catenin transactivating complex
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
- Neddylation
|
|
|
|
USP9X |
ubiquitin specific peptidase 9 X-linked |
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Ub-specific processing proteases
- Synthesis of active ubiquitin: roles of E1 and E2 enzymes
- Peroxisomal protein import
- Peroxisomal protein import
- Amyloid fiber formation
|
|
|
|
ASH2L |
ASH2 like, histone lysine methyltransferase complex subunit |
- Formation of the beta-catenin:TCF transactivating complex
- PKMTs methylate histone lysines
- Deactivation of the beta-catenin transactivating complex
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
|
|
|
|
CDC34 |
cell division cycle 34, ubiqiutin conjugating enzyme |
- Downstream TCR signaling
- FCERI mediated NF-kB activation
- CLEC7A (Dectin-1) signaling
- Synthesis of active ubiquitin: roles of E1 and E2 enzymes
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
CDH2 |
cadherin 2 |
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- Adherens junctions interactions
- Myogenesis
- Myogenesis
- Post-translational protein phosphorylation
|
|
|
|
CTNNA1 |
catenin alpha 1 |
- Adherens junctions interactions
- VEGFR2 mediated vascular permeability
- Myogenesis
- Myogenesis
- RHO GTPases activate IQGAPs
|
|
|
|
KMT2A |
lysine methyltransferase 2A |
- PKMTs methylate histone lysines
- RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- Transcriptional regulation of granulopoiesis
|
|
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
|